Company

Bodor Laboratories, Inc.

Founded in 2006 by Prof. Nicholas S. Bodor to further the development and therapeutic potential of his novel Retrometabolic Drug Design and Targeting concepts. Traditionally, development of therapeutics targeted to exploit newly identified pathways results in exceptionally high rates of drug failures, either through lack of effectiveness or unacceptable toxicity. The Retrometabolic Drug Design process provides a means of capitalizing on known pathways and therapeutics to develop novel compounds that have considerably less side-effects and clear paths to approval success. We have utilized this drug design approach to build a substantive portfolio of intellectual property, which we are able to develop through collaborative partnerships to drive these ideas to the market.

Who We Are

Nicholas S. Bodor, Ph.D., D.Sc., d.h.c. (multi)

HoF (multi), Founding Chairman, President & CSO

Dr. Bodor, an internationally recognized leader in drug discovery, drug design and delivery, has introduced revolutionary, general and comprehensive drug design and drug targeting concepts known as retrometabolic drug design approaches. Dr. Bodor joined the University of Florida as Professor and Chairman of the Medicinal Chemistry Department and was soon promoted to Graduate Research Professor. He established the Center for Drug Discovery at the College of Pharmacy in 1986, serving as its Executive Director. Dr. Bodor took a leave of absence from his academic posts to accept appointments as the IVAX Corporation’s Chief Scientific Officer and Managing Director of the IVAX Drug Research Institute (Budapest) from 2000 – 2005. He founded Bodor Laboratories, Inc. in 2006 in order to further develop his drug design strategies. He has published more than 520 research articles, holds some 250 patents, and is on the editorial boards of several international scientific journals. Among his honors, he is an elected Fellow of APS, AAPS, AAAS, and ACCP. Named “The 1984 Florida Scientist of the Year” he received the first AAPS Research Achievement Award in Medicinal and Natural Product Chemistry in 1988, and the APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry in 1989. He was the first Nagai Foundation Tokyo International Fellowship recipient, and received the 1997 AACP Volwiler Research Achievement Award. An honorary Doctor of Science degree was conferred upon Dr. Bodor by UF in 2005, and in 2007, he received the AAPS Distinguished Pharmaceutical Scientist Award. Dr. Bodor was inducted in to the American Chemical Society’s Hall of Fame, Medicinal Chemistry Division, in August 2012. Recognitions by his home country of Hungary for his scientific achievements include an honorary Doctor of Science degree from the Technical University of Budapest, as well as the Doctor Honoris Causa degree from the Medical University of Debrecen. Elected to the Hungarian National Academy of Sciences in 1995, Dr. Bodor was awarded the Gold Cross of Merit of the Hungarian Republic in 2004. In 2010, he received the Fabinyi Prize of the Hungarian Chemical Society and in that same year, was awarded the Commander’s Cross of the Order of Merit of the Hungarian Republic. Dr. Bodor received his B.S./M.S. degree in Organic Chemistry at Bolyai University in Transylvania, and his Ph.D. degree from the University of Babes-Bolyai, Cluj and the Romanian National Academy of Sciences.

Click Here For Full CV

Erik T. Bodor, Ph.D., MBA

CEO & VP, Research

Dr. Bodor has worked with various pharmaceutical and nutraceutical companies, assisting in strategic market analysis and business development. He also has over 20 years of biomedical research experience, including an Alexander von Humboldt research fellowship at the University of Heidelberg in Germany. Dr. Bodor received bachelors degrees in both Chemistry and Anthropology from Emory University, his doctorate in Pharmacology from the University of North Carolina at Chapel Hill, and his MBA from Columbia University.

John F. Howes, Ph.D.

VP, Drug Development

Dr. Howes has over 40 years of experience in regulatory affairs and clinical development at both start-up and established pharmaceutical companies. Dr. Howes has held executive positions in various companies where he directly contributed to IND, NDA, and approval filings of numerous drugs, most notably the ophthalmic drugs Lotemax® and Alrex®. Dr. Howes received a bachelors degree in Pharmacy from the University of London, where he also received his doctorate in Pharmacology.

Nicole Z. Bodor, Ph.D.

VP & Director of Intellectual Property

Dr. Bodor received her Bachelor’s Degree in Psychology from Bryn Mawr College, where her academic work included completion of an honors thesis entailing her own research, a one-year clinical research study and the writing of IRB proposals. She started her doctoral work at the University of Florida and then transferred to the University of Texas at Austin. After receiving her Ph.D. in Psychology there in 2002, she completed a one-year clinical psychology internship at the North Chicago V.A. Medical Center and an additional two years’ postdoctoral work in Clinical Psychology at the Albuquerque Veterans Affairs Medical Center. Her research experience spans more than six years, and she also has an additional 5 years’ clinical experience in both Austin and Gainesville.

Elvie Guy

Business and Intellectual Property Manager

A Florida native, Mrs. Guy’s career working for Dr. Bodor started in 1996 when she accepted the position of Office Manager at the University of Florida’s Center for Drug Discovery in Gainesville under his direction. Among other duties there, she assisted with the event planning for the Retrometabolism Based Drug Design and Targeting Conference biennial international symposia series that Dr. Bodor started in 1997. When Dr. Bodor took an extended leave of absence from the University of Florida to develop the research program at the IVAX Corporation, Mrs. Guy left UF and followed him to Miami to work as his executive assistant. Upon Dr. Bodor’s retirement from IVAX, Mrs. Guy returned, to Gainesville in 2006 to work again for the UF College of Pharmacy, this time as an executive assistant for the Office of the Dean. In 2012 she left UF a second time in order to accept her current position at Bodor Laboratories. In addition to handling a variety of day-to-day administrative functions, she also manages the records of the company’s extensive patent portfolio.